Abstracts tagged "scleroderma and systemic sclerosis"

Abstract Number: 1878 • 2018 ACR/ARHP Annual Meeting
Immunosuppression in Diffuse Systemic Sclerosis Improves Outcomes Using a Novel Composite Response Index
Boyang Zheng¹, Mianbo Wang² and Murray Baron³, ¹Rheumatology, McGill University Health Center (MUHC), Montreal, QC, Canada, ²Lady Davis Institute for Medical Research, Montreal, QC, Canada, ³Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada
Background/Purpose: Diffuse systemic sclerosis (dcSSc) is a devastating multi-organ disease where the mainstay of treatment is immunosuppression. Data on these therapies are mostly based on…
Abstract Number: 1879 • 2018 ACR/ARHP Annual Meeting
The Effects of Riociguat on Raynaud’s Phenomenon and Digital Ulcers in Patients with Diffuse Systemic Sclerosis: Results from the Phase IIb RISE-SSc Study
Dinesh Khanna¹, Yannick Allanore², Christopher P. Denton³, Masataka Kuwana⁴, Marco Matucci-Cerinic⁵, Janet E. Pope⁶, Janethe Pena⁷, Kaisa Laapas⁸, Zhen Yao⁹ and Oliver Distler¹⁰, ¹Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ²Rheumatology A Department, Cochin Hospital, Paris Descartes University, Sorbonne Paris Cité, Paris, France, ³UCL Division of Medicine, Royal Free Campus, London, United Kingdom, ⁴Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ⁵Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ⁶Department of Medicine, University of Western Ontario, London, ON, Canada, ⁷Clinical Development, Bayer US LLC, Whippany, NJ, ⁸StatFinn Oy, Espoo, Finland, ⁹Bayer AG, Berlin, Germany, ¹⁰Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: The soluble guanylate cyclase stimulator riociguat is approved for the treatment of pulmonary arterial hypertension associated with connective tissue disease. It was anticipated that…
Abstract Number: 814 • 2018 ACR/ARHP Annual Meeting
NON Diffuse SSc, Peripheral Neuropathy, Concomitant Sjogren Syndrome and ANTI-RNA Polymerase III Represent Risk Factors for the Higher Frequency of Cancer in a Large Single Cohort of Patients with Systemic Sclerosis
Ana Paula Luppino-Assad¹, Adriana Bortoluzzo², Henrique Carriço da Silva³, Danieli Andrade⁴ and Percival Sampaio-Barros⁴, ¹Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR., sao paulo, Brazil, ²c Instituto Insper de Educação e Pesquisa, São Paulo, SP, Brasil, sao paulo, Brazil, ³Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR., SAO PAULO, Brazil, ⁴Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR., São Paulo, Brazil
Background/Purpose: A higher prevalence of cancer has been described in patients with systemic sclerosis (SSc), but the magnitude of this risk and the type of…
Abstract Number: 903 • 2018 ACR/ARHP Annual Meeting
Riociguat in Patients with Early Diffuse Cutaneous Systemic Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Phase IIb Study (RISE-SSc)
Oliver Distler¹, Yannick Allanore², Christopher P. Denton³, Masataka Kuwana⁴, Marco Matucci-Cerinic⁵, Janet E. Pope⁶, Janethe Pena⁷, Kaisa Laapas⁸, Zhen Yao⁹ and Dinesh Khanna¹⁰, ¹Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²Rheumatology A Department, Cochin Hospital, Paris Descartes University, Sorbonne Paris Cité, Paris, France, ³UCL Division of Medicine, Royal Free Campus, London, United Kingdom, ⁴Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ⁵Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ⁶Department of Medicine, University of Western Ontario, London, ON, Canada, ⁷Clinical Development, Bayer US LLC, Whippany, NJ, ⁸StatFinn Oy, Espoo, Finland, ⁹Bayer Healthcare Co. Ltd.,, Beijing, China, ¹⁰Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI
Background/Purpose: There are few disease-modifying therapies for the treatment of systemic sclerosis (SSc), particularly the more severe diffuse cutaneous form (dcSSc). The soluble guanylate cyclase…
Abstract Number: 1108 • 2018 ACR/ARHP Annual Meeting
Antibody Repertoire Dynamics in Systemic Sclerosis after Myeloablative Autologous Hematopoietic Stem-Cell Transplantation or Cyclophosphamide Treatment
Julia Z. Adamska^1,2, Leslie Crofford³, Daniel E. Furst^4,5, Ellen Goldmuntz⁶, Lynette Keyes-Elstein⁷, Maureen D. Mayes⁸, Peter McSweeney⁹, Richard Nash⁹, Ashley Pinckney¹⁰, Beverly Welch¹¹, Keith Sullivan¹² and William H. Robinson^1,2, ¹Stanford University, Stanford, CA, ²VA Palo Alto Health Care System, Palo Alto, CA, ³Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN, ⁴University of California Los Angeles, Los Angeles, CA, ⁵University of Washington, Seattle, WA, ⁶NIAID, NIH, Bethesda, MD, ⁷Clinical Statistics, Rho Federal Systems, Inc., Chapel Hill, NC, ⁸Rheumatology, University of Texas McGovern Medical School, Houston, TX, ⁹Colorado Blood Cancer Institute, Denver, CO, ¹⁰Rho Federal Systems, Inc., Chapel Hill, NC, ¹¹National Institutes of Health, Bethesda, MD, ¹²Duke University Medical Center, Durham, NC
Background/Purpose: Myeloablative autologous hematopoietic stem-cell transplantation (HSCT) was recently demonstrated to provide benefit over monthly cyclophosphamide (CYC) in the treatment of diffuse cutaneous systemic sclerosis…
Abstract Number: 1725 • 2018 ACR/ARHP Annual Meeting
Fecal Microbiota Transplantation in Patients with Systemic Sclerosis- a Pilot Study
Håvard Fretheim¹, Oyvind Midtvedt¹, Anders Heiervang Tennøe¹, Henriette Didriksen¹, Torhild Garen¹, Espen Bækkevold¹, Johannes R. Hov¹, Knut EA Lundin², Marius Trøseid¹, Øyvind Molberg¹ and Anna-Maria Hoffmann-Vold¹, ¹Oslo University Hospital, Oslo, Norway, ²Dept of gastroenterology, Oslo University Hospital, Oslo, Norway
Background/Purpose: Up to 90% of patients with systemic sclerosis (SSc) have symptoms from the gastrointestinal (GI) tract. Earlier studies have shown a distinct alteration of…
Abstract Number: 1742 • 2018 ACR/ARHP Annual Meeting
Disease-Specific Autoantibodies Associate with Remarkably Different Risk of Development of Significant Lung Fibrosis in Systemic Sclerosis
Svetlana I. Nihtyanova¹, Alper Sari², Anna Leslie³, Voon H. Ong⁴ and Christopher P. Denton⁵, ¹Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, ²Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ³Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, ⁴Division of Medicine, University College London, London, United Kingdom, ⁵University College London, London, United Kingdom
Background/Purpose: Pulmonary fibrosis (PF) is a leading cause of disease-related death in SSc patients. Some studies suggest that the timing of PF development differs between…
Abstract Number: 1695 • 2017 ACR/ARHP Annual Meeting
Baseline Characteristics and Outcomes in a Retrospective Cohort of Patients with Systemic Sclerosis Related Interstitial Lung Disease
Robert L. Mango¹, Eric L. Matteson², Cynthia S. Crowson³, Jay H. Ryu⁴ and Ashima Makol², ¹Internal Medicine, Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, MN, ²Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁴Division of Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN
Background/Purpose: Interstitial lung disease (ILD) is a major contributor to morbidity and mortality in systemic sclerosis (SSc). We sought to identify the distribution of clinical…
Abstract Number: 1713 • 2017 ACR/ARHP Annual Meeting
Defining Genetic Risk for Scleroderma Renal Crisis in RNA-Polymerase III Antibody Positive Patients
Edward Stern¹, Sandra Guerra¹, Harry Chinque¹, David Gonzalez Serna², Markella Ponticos¹, Javier Martin², Maureen D. Mayes³, Shervin Assassi⁴, Carmen Fonseca¹ and Christopher Denton⁵, ¹UCL Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom, ²Instituto de Parasitología y Biomedicina López-Neyra, Granada, Spain, ³Internal Medicine/Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ⁴University of Texas McGovern Medical School, Houston, TX, ⁵Department of Rheumatology, University College London, Royal Free Hospital, London, United Kingdom
Background/Purpose: Scleroderma renal crisis (SRC), characterised by accelerated hypertension and acute kidney injury, is a life-threatening complication of systemic sclerosis (SSc). Most SSc cases have…
Abstract Number: 1922 • 2017 ACR/ARHP Annual Meeting
Cell Type Specific Gene Expression Analysis of Early Systemic Sclerosis Skin Shows a Prominent Activation Pattern of Innate and Adaptive Immune System in the Prospective Registry for Early Systemic Sclerosis (PRESS) Cohort
Shervin Assassi¹, Dinesh Khanna², Monique Hinchcliff³, Virginia D. Steen⁴, Faye Hant⁵, Jessica K. Gordon⁶, Ami A. Shah⁷, Jun Ying⁸, William Swindell⁹, Wenjin Zheng¹⁰, Lisha Zhu¹⁰, Victoria K. Shanmugam¹¹, Robyn T. Domsic¹², Flavia V. Castelino¹³, Elana J. Bernstein¹⁴ and Tracy M. Frech¹⁵, ¹University of Texas McGovern Medical School, Houston, TX, ²University of Michigan, Ann Arbor, MI, ³Rheumatology, Northwestern Medicine, Chicago, IL, ⁴Rheumatology, MedStar Georgetown University Hospital, Washington, DC, ⁵Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ⁶Rheumatology, Hospital for Special Surgery, New York, NY, ⁷Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁸Department of Internal Medicine - Rheumatology, University of Texas McGovern Medical School, Houston, TX, ⁹Dermatology, University of Michigan - Ann Arbor, Ann Arbor, MI, ¹⁰University of Texas - School of Biomedical Informatics, Houston, TX, ¹¹Rheumatology, The George Washington University, Washington, DC, ¹²Rheumatology, University of Pittsburgh, Pittsburgh, PA, ¹³Rheumatology, Harvard Medical School, Boston, MA, ¹⁴Rheumatology, Columbia University, New York, NY, ¹⁵Division of Rheumatology, University of Utah, Salt Lake City, UT
Background/Purpose: To examine the global gene expression profile in patients with very early diffuse systemic sclerosis (SSc). Methods: Skin biopsies were obtained from patients enrolled…
Abstract Number: 1923 • 2017 ACR/ARHP Annual Meeting
Single Cell RNA Sequencing Reveals a Signature of Endothelial Injury in Scleroderma Skin
Sokratis Apostolidis¹, Giuseppina Stifano², Tracy Tabib³, Lisa Rice², Christina Morse³, Bashar Kahaleh⁴ and Robert A. Lafyatis³, ¹Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, ²Boston University School of Medicine, Boston, MA, ³Medicine, Rheumatology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁴Medicine/Rheumatology, University of Toledo, Toledo, OH
Background/Purpose: Vascular injury is a hallmark event in the pathogenesis of Systemic Sclerosis (SSc). Endothelial dysfunction happens early in the course of the disease and…
Abstract Number: 2665 • 2017 ACR/ARHP Annual Meeting
Mortality in an Early Diffuse Cutaneous Systemic Sclerosis Cohort—Data from the Prospective Registry for Early Systemic Sclerosis
Tracy M. Frech¹, Shervin Assassi², Elana J. Bernstein³, Flavia V. Castelino⁴, Robyn T. Domsic⁵, Jessica K. Gordon⁶, Faye Hant⁷, Monique Hinchcliff⁸, Bernie LaSalle⁹, Victoria K. Shanmugam¹⁰, Virginia D. Steen¹¹ and Dinesh Khanna¹², ¹Division of Rheumatology, University of Utah, Salt Lake City, UT, ²University of Texas McGovern Medical School, Houston, TX, ³Department of Medicine, Division of Rheumatology, Columbia University, New York, NY, ⁴Rheumatology, Allergy, Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁵Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁶Rheumatology, Hospital for Special Surgery, New York, NY, ⁷Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ⁸Department of Medicine Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁹University of Utah, Salt Lake City, UT, ¹⁰Rheumatology, The George Washington University, Washington, DC, ¹¹Division of Rheumatology, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC, ¹²University of Michigan, Ann Arbor, MI
Background/Purpose: The Prospective Registry of Early Systemic Sclerosis (PRESS) cohort is an early diffuse cutaneous systemic sclerosis (dcSSc) that provides an opportunity to assess the…
Abstract Number: 2674 • 2017 ACR/ARHP Annual Meeting
The Association between the Extent of Skin Thickness and Organ Involvement, Function and Quality of Life in Early Diffuse Cutaneous Systemic Sclerosis
Janet E. Pope¹, Murray Baron², Tatiana Nevskaya³, Carl Baxter⁴ and Dena Ramey⁵, ¹Medicine, Divsion of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, ²Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada, ³Rheumatology Division, St. Joseph’s Health Care London, London, ON, Canada, ⁴Global Outcomes Research, MSD Ltd, Hoddesdon, United Kingdom, ⁵Epidemiology, Merck & Co., Upper Gwynedd, PA
Background/Purpose: To estimate whether severity of skin thickness is associated with disease severity, function, quality of life (QoL) and progression of internal organ involvement over…
Abstract Number: 257 • 2017 ACR/ARHP Annual Meeting
The Use of Positron Emission Tomography (PET)-Scan for the Quantitative Assessment of Interstitial Lung Disease in Systemic Sclerosis
Daphne Peelen¹, Ben Zwezerijnen², Esther Nossent¹, Lilian Meijboom¹, Otto Hoekstra³, Conny van der Laken⁴ and Alexandre Voskuyl⁴, ¹VUmc, Amsterdam, Netherlands, ²Nuclear Medicine, VUmc, Amsterdam, Netherlands, ³Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands, Amsterdam, Netherlands, ⁴Department of Rheumatology, Amsterdam Rheumatology and immunology Center - location VU University Medical Center, Amsterdam, The Netherlands, Amsterdam, Netherlands
Background/Purpose: Interstitial lung disease (ILD) in systemic sclerosis is treated by immunosuppressive drugs (e.g. cyclophosphamide), aimed at reduction of inflammatory response . Differentiation between inflamed…
Abstract Number: 2690 • 2017 ACR/ARHP Annual Meeting
Plasma D-Dimer Levels Are More Frequently Elevated in Limited Than Diffuse Cutaneous Systemic Sclerosis but Do Not Reflect Disease Duration or Vasculopathy
Anna Gill¹, Svetlana I. Nihtyanova², Pratima Chowdary³ and Christopher Denton¹, ¹Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, ²Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, ³Department of Haematology, Royal Free Hospital, London, United Kingdom
Background/Purpose: D-dimers are degradation products of cross linked fibrin and are biomarkers of activation of the coagulation system. Plasma D-dimer levels can be raised in…

1
2
3
…
8
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].